Register for our free email digests:
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Restoring the eyes' ability to accommodate and seamlessly focus on near and far objects continues to be the holy grail in ophthalmology. Accommodating intraocular lenses offer one approach to tackle presbyopia and allow patients the possibility of eschewing reading glasses. LensGen is one company going down that road and it successfully raised $21m in series A financing – with major optical lens maker Hoya among its backers – in April to advance its fluid-based accommodating IOL, Juvene.
Latest From Innovation
Virtual reality is seeing an upsurge in use by mental health practitioners for treating conditions such as post-traumatic stress disorder, panic disorders and anxiety in a safe and controlled manner. With the advent of affordable VR headsets and technological advances, companies and researchers worldwide are seizing on the opportunity to bring such techniques as VR exposure therapy and cognitive behavioral therapy to telemedicine, specialty clinics and directly to consumers to improve outcomes and better lives.
The positive growth trend seen in Israel's digital health industry is galvanizing big players like Medtronic into action to start developing and recognizing synergistic technologies for future business. Medtech Insight met with members of MindUP, Israel's first digital health incubator and the result of a cross-industry partnership, at the MiXiii Biomed conference in Tel Aviv, to discover how the joint venture is driving the next generation of digital innovations.
Early-stage UK businesses took center stage at a medtech-focused investor event held as part of London's Tech Week. The weeklong festival of events, June 12-16, are intended to strengthen London's status as a global tech hub and celebrate cutting-edge innovation.
INS 2017: Neuromodulation's Future Features Innovative Power Source, Materials And Treatment Protocols
Neuromodulation technology is advancing at breakneck speed, as physicians, academic, and industry innovators deepen their understanding of the field and learn what works and what doesn't. At the Innovations Day held during the 13th world congress of the International Neuromodulation Society in Edinburgh, Scotland, Medtech Insight highlights the notable new techs that are in the pipeline of emerging companies.
Only 10 approvals from outside the US were recorded in May in Medtech Insight's approvals tracker. Half of those were for in vitro diagnostics, including three for companion diagnostic for cancer drugs.
Claret Medical plans to start rolling out the TAVR accessory immediately at clinical trial centers, with full market release expected in 2018. The company is also trying to get a Medicare add-on payment.
One-month results from the LUCY trial show that Endologix Ovation abdominal aortic aneurysm (AAA) stent graft, designed specifically for female anatomy, could make 28% more women eligible for a AAA endograft. LUCY, the first study to specifically evaluate endovascular aneurysm repair in women, is part of a trend of research focused on women's outcomes with cardiovascular devices.
REDUCE is the first trial of patent foramen ovale closure device to show statistically significant reduction in stroke recurrence in its primary intent-to-treat analysis. The results, presented at the European Stroke Organisation Conference in Prague, will support Gore's application for Cardioform to the US FDA by the end of the year.
Australian closed-loop neuromodulation specialist Saluda Medical looks to be going from strength to strength as it welcomes a $40m injection of fresh funds from investors including the GSK fund, Action Potential Venture Capital. The investment will further support Saluda's expanding clinical activities, from which positive three- and six-month data on the safety and performance of its Evoke closed-loop spinal cord stimulator were presented at the recent 13th International Neuromodulation Society congress in Edinburgh, Scotland.
You must sign in to use this functionality
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.